-
India Launches Anti-Dumping Campaign Against Chinese Vitamin B12 and Ceftriaxone Sodium Producers
•
In a strategic response to India’s Ministry of Commerce and Industry’s (MOFCOM) anti-dumping ruling against Chinese vitamin A palmitate producers, Indian pharmaceutical firms have initiated a new campaign on March 13. This time, the focus is on China’s manufacturers of vitamin B12 and ceftriaxone sodium, with customs codes 29362610 and…
-
Novartis Sees 15% Global Sales Growth and Significant Investment in China for 2006
•
Novartis, a multinational pharmaceutical giant, has reported a robust sales revenue of nearly US$275.7 million in the China market for the year 2006. This figure comes as part of a broader global sales increase of 15%, propelling the company’s total global revenue to US$37 billion, with net income soaring by…
-
Ruijin Hospital Researchers Uncover Five New Mutations in Rare 17OHD Endocrine Disorder
•
In a significant advancement in endocrine research, scientists within the Endocrine Department at Ruijin Hospital have identified five novel mutations through clinical and genetic examinations of eight patients diagnosed with 17 alpha-Hydroxylase/17,20 Lyase Deficiency (17OHD). The most prevalent genotype observed was D487-F489del. Structural protein analysis and in vitro studies have…
-
China’s SFDA Mandates Official Position Rotation to Boost Transparency
•
China’s State Food and Drug Administration (SFDA) is poised to embrace a new era of transparency with the announcement of its forthcoming measures by Shao Mingli, the agency’s head. Scheduled for the second half of 2007, the SFDA is preparing to initiate regular press conferences, a proactive step designed to…
-
Guangdong’s ‘Sunlight Purchase’ System Sparks Drug Pricing War and Uncovers Pricing Anomalies
•
Since 2007, Guangdong province’s medical facilities have utilized an online procurement system known as “Sunlight Purchase” for drug acquisitions. However, this system has inadvertently ignited an unprecedented pricing war, simultaneously exposing deep-rooted issues within drug pricing structures. A pivotal conference convened on March 31 by the Guangdong Drug Purchase Service…
-
Ruijin Hospital Unveils Five New Mutations in Rare Adrenal Hyperplasia Study
•
In a groundbreaking study, Ruijin Hospital’s Endocrine Department researchers identified five novel mutations in 17 alpha-Hydroxylase/17,20 Lyase Deficiency (17OHD), a rare inherited adrenal hyperplasia. The research, spanning three years and encompassing eight patients from seven families, unveiled six mutations within the CYP17A1 gene, with five being previously unreported. The D487-F489del…
-
SFDA Embraces Transparency: Regular Press Briefings and Personnel Rotations Announced
•
China’s State Food and Drug Administration (SFDA) is gearing up for a transparency overhaul, with its head, Shao Mingli, unveiling a slate of reforms aimed at bolstering public and media scrutiny. Scheduled for the latter half of 2007, the agency will initiate a series of regular press conferences, marking a…
-
China’s Western Pharmaceutical Exports Soar 23% in 2006, Led by Antibiotics
•
The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE) has reported a robust surge in China’s export values for Western pharmaceutical preparations in 2006. The year-on-year growth rate reached a significant 23%, with the total value amassing to US$504 million. Among the various categories,…
ADC / XDC AstraZeneca Auto-immune AZ Biosimilars Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
